MIC-Lx is under clinical development by TolerogenixX and currently in Phase II for Kidney Transplant Rejection. According to GlobalData, Phase II drugs for Kidney Transplant Rejection have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MIC-Lx’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MIC-Lx is under investigation for the treatment of multiple sclerosis (MS), kidney transplant rejection and systemic lupus erythematosus (SLE). It is administered through intravenous route.
TolerogenixX is a biotechnology company that develops patented and clinically tested alternative cell therapy technique for individualised immunosuppression to treat post-transplant patients and those suffering from numerous autoimmune diseases. The company offers TolerogenixX technology which is tailored immunosuppressive therapy by the production of tolerogenic mitomycin C-treated peripheral blood mononuclear cells (MIC) cells through incubation of specific white blood cells with the antiproliferative substance Mitomycin C. The company conducts its phase I clinical trial on kidney transplantation and renal transplantation. It’s therapy is supplied in a kit, finds application in any hospital across the globe for the treatment of organ transplant recipients and various autoimmune diseases. TolerogenixX is headquartered in Heidelberg, Germany.
For a complete picture of MIC-Lx’s drug-specific PTSR and LoA scores, buy the report here.